DB
TVTX icon

Dmitry Balyasny’s Travere Therapeutics TVTX Stock Holding History

Dmitry Balyasny’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Buy
+35,385
New +$1.57M ﹤0.01% 1822
2025
Q4 		– Sell
-21,988
Closed -$526K – 3568
2025
Q3 		$526K Buy
+21,988
New +$413K ﹤0.01% 2384
2025
Q2 		– Sell
-190,272
Closed -$3.41M – 3365
2025
Q1 		$3.41M Buy
+190,272
New +$3.86M 0.01% 1436
2024
Q4 		– Sell
-1,285,379
Closed -$18M – 3273
2024
Q3 		$18M Buy
+1,285,379
New +$13.4M 0.03% 682
2023
Q3 		– Sell
-326,570
Closed -$5.02M – 2746
2023
Q2 		$5.02M Buy
+326,570
New +$5.94M 0.01% 1057
2023
Q1 		– Sell
-67,349
Closed -$1.42M – 3175
2022
Q4 		$1.42M Sell
67,349
-344,269
-84% -$7.3M ﹤0.01% 1548
2022
Q3 		$10.1M Buy
411,618
+110,412
+37% +$2.85M 0.03% 679
2022
Q2 		$7.3M Buy
+301,206
New +$7.58M 0.02% 780
2019
Q2 		– Sell
-20,534
Closed -$465K – 1739
2019
Q1 		$465K Buy
20,534
+10,613
+107% +$235K ﹤0.01% 1222
2018
Q4 		$225K Buy
+9,921
New +$247K ﹤0.01% 1282
2017
Q2 		– Sell
-109,072
Closed -$2.01M – 1755
2017
Q1 		$2.01M Buy
+109,072
New +$2.13M 0.01% 907
2016
Q4 		– Sell
-45,000
Closed -$1.01M – 1485
2016
Q3 		$1.01M Buy
+45,000
New +$857K 0.01% 685
2015
Q4 		– Sell
-18,950
Closed -$384K – 1455
2015
Q3 		$384K Buy
+18,950
New +$561K ﹤0.01% 859

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's TVTX Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 35,385 shares worth $2.01M. The stake represents ﹤0.01% of the portfolio and ranks #1822 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in TVTX as recently as Q3 2025.

Dmitry Balyasny first reported a position in TVTX in Q3 2015 and has held it in 13 quarters since. The position peaked at $18M in Q3 2024. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Dmitry Balyasny held 35,385 shares of Travere Therapeutics worth $2.01M as of Q2 2026.
  • Travere Therapeutics was a new Dmitry Balyasny position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1822 holding.
  • Dmitry Balyasny first reported a position in Travere Therapeutics in Q3 2015 and has held it in 13 quarters since.
  • Dmitry Balyasny's Travere Therapeutics position peaked at $18M in Q3 2024.
  • 317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.